Panobinostat

Histone Deacetylase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Panobinostat is an ofm drug in the Histone Deacetylase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2015. Its mechanism of action is classified as Cytochrome P450 2D6 Inhibitors and Histone Deacetylase Inhibitors. DrugCentral lists 18 molecular targets, including HDAC4, HDAC2 and HDAC5. Recorded indications include Multiple myeloma and Primary cutaneous T-cell lymphoma.

• Approval status: ofm (first approved 2015 by the FDA).
• Drug class: Histone Deacetylase Inhibitor.
• Mechanism of action: Cytochrome P450 2D6 Inhibitors; Histone Deacetylase Inhibitors.
• Molecular targets: HDAC4, HDAC2, HDAC5 and HDAC6 (18 listed in DrugCentral).
• Indications: Multiple myeloma and Primary cutaneous T-cell lymphoma.
• ATC code: L01XH03 (Histone deacetylase (HDAC) inhibitors).
• Molecular formula: C21H23N3O2; molecular weight 349.43 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Multiple myeloma
• Primary cutaneous T-cell lymphoma

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 2D6 Inhibitors; Histone Deacetylase Inhibitors
• Established pharmacologic class: Histone Deacetylase Inhibitor

Molecular targets (18)

Target	Gene	Action	Activity
Histone deacetylase 4	HDAC4	inhibitor	Ki 9.22
Histone deacetylase 2	HDAC2	inhibitor	Ki 9.19
Histone deacetylase 5	HDAC5	inhibitor	Ki 9.15
Histone deacetylase 6	HDAC6	inhibitor	Ki 9.15
Histone deacetylase 1	HDAC1	inhibitor	Ki 9.00
Histone deacetylase 3	HDAC3	inhibitor	Ki 8.96
Histone deacetylase 9	HDAC9	inhibitor	Ki 8.92
Histone deacetylase	HDAC1	unknown	IC50 8.74
Histone deacetylase 7	HDAC7	inhibitor	Ki 8.64
Histone deacetylase 11	HDAC11	inhibitor	Ki 8.46
Phosphatidylinositol 3-kinase catalytic subunit type 3	PIK3C3	unknown	IC50 8.30
Bromodomain-containing protein 4	BRD4	unknown	IC50 8.30
Histone deacetylase	PfHDAC1	unknown	IC50 8.00
Histone deacetylase 8	HDAC8	inhibitor	Ki 7.66
Histone deacetylase 10	HDAC10	inhibitor	Ki 7.51
Protein Tat	tat	unknown	EC50 6.89
Histone deacetylase 8	HDAC8	unknown	IC50 6.35
Methylcytosine dioxygenase TET2	TET2	unknown	IC50 5.42

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2015-08-28	EMA	—	—	Yes
2015-02-23	FDA	—	NOVARTIS PHARMS CORP

ATC classification

ATC code	Therapeutic hierarchy
L01XH03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Histone deacetylase (HDAC) inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Platelet count decreased	258.7
Malignant neoplasm progression	255.3
Diarrhoea	239.4
Plasma cell myeloma	161.4
Thrombocytopenia	146.7
Death	136.7
White blood cell count decreased	64.4
Disease progression	58.4
Neutrophil count decreased	56.3
Concomitant disease aggravated	55.4
Morganella infection	52.6
Anaemia	48.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Panobinostat is on its molecule page.

• Molecular formula: C₂₁H₂₃N₃O₂
• Molecular weight: 349.43 g/mol
• CAS number: —
• InChIKey: FPOHNWQLNRZRFC-ZHACJKMWSA-N
• PubChem CID: 6918837

CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Panobinostat used for?

DrugCentral lists the following indications for Panobinostat: Multiple myeloma and Primary cutaneous T-cell lymphoma.

How does Panobinostat work?

Panobinostat is classified as Cytochrome P450 2D6 Inhibitors and Histone Deacetylase Inhibitors; its molecular targets in DrugCentral include HDAC4 (inhibitor), HDAC2 (inhibitor), HDAC5 (inhibitor) and HDAC6 (inhibitor).

When was Panobinostat first approved?

Panobinostat was first approved by the FDA in 2015.

What drug class does Panobinostat belong to?

Panobinostat is in the Histone Deacetylase Inhibitor class.

What is the chemical formula of Panobinostat?

Panobinostat has the molecular formula C21H23N3O2 and a molecular weight of 349.43 g/mol.

Sources

• DrugCentral drug card 4682 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3545368 — compound record and bioactivity
• PubChem CID 6918837 — chemical identifiers
• DrugBank DB06603 — drug record
• FDA UNII 9647FM7Y3Z — substance identity
• DailyMed: FDA labels for Panobinostat — current prescribing information (label search)
• UniProt P56524 (HDAC4) — target protein
• UniProt Q92769 (HDAC2) — target protein
• UniProt Q9UQL6 (HDAC5) — target protein
• UniProt Q9UBN7 (HDAC6) — target protein
• UniProt Q13547 (HDAC1) — target protein
• UniProt O15379 (HDAC3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.